Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy

HFCAS OpenIR

	Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy
其他题名	Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy
	2016
发表期刊	CHINESE MEDICAL JOURNAL
ISSN	0366-6999
摘要	Background: Conflicting results about the association between expression level of excision repair cross-complementation group 1 (ERCC1) and clinical outcome in patients with colorectal cancer (CRC) receiving chemotherapy have been reported. Thus, we searched the available articles and performed the meta-analysis to elucidate the prognostic role of ERCC 1 expression in patients with CRC.
其他摘要	Background: Conflicting results about the association between expression level of excision repair cross-complementation group 1 (ERCC1) and clinical outcome in patients with colorectal cancer (CRC) receiving chemotherapy have been reported. Thus, we searched the available articles and performed the meta-analysis to elucidate the prognostic role of ERCC1 expression in patients with CRC. Methods: A thorough literature search using PubMed (Medline), Embase, Cochrane Library, Web of Science databases, and Chinese Science Citation Database was conducted to obtain the relevant studies. Pooled hazard ratios ( HR s) or odds ratios ( OR s) with 95% confidence intervals ( CI s) were calculated to estimate the results. Results: A total of 11 studies were finally enrolled in this meta-analysis. Compared with patients with lower ERCC1 expression, patients with higher ERCC1 expression tended to have unfavorable overall survival (OS) ( HR = 2.325, 95% CI : 1.720–3.143, P < 0.001), progression-free survival (PFS) ( HR = 1.917, 95% CI : 1.366–2.691, P < 0.001) and poor response to chemotherapy ( OR = 0.491, 95% CI : 0.243–0.990, P = 0.047). Subgroup analyses by treatment setting, ethnicity, HR extraction, detection methods, survival analysis, and study design demonstrated that our results were robust. Conclusions: ERCC1 expression may be taken as an effective prognostic factor predicting the response to chemotherapy, OS, and PFS. Further studies with better study design and longer follow-up are warranted in order to gain a deeper understanding of ERCC1's prognostic value.
关键词	PLATINUM-BASED CHEMOTHERAPY CELL LUNG-CANCER III COLON-CANCER THYMIDYLATE SYNTHASE ADJUVANT CHEMOTHERAPY PREDICTIVE-VALUE GASTRIC-CANCER LINK REPAIR ERCC1 EXPRESSION Colorectal Cancer Excision Repair Cross-complementation Group 1 Prognosis
收录类别	CSCD
语种	英语
资助项目	[National High-Tech Research and Development Program of China (863 Program)]
CSCD记录号	CSCD:5650420
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/68191
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy[J]. CHINESE MEDICAL JOURNAL,2016,129.
APA	(2016).Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.CHINESE MEDICAL JOURNAL,129.
MLA	"Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy".CHINESE MEDICAL JOURNAL 129(2016).